{"title":"Ferritin-displayed engineered sCAR1 nanoparticles as a receptor-decoy antiviral strategy against Coxsackievirus B-associated inflammation","authors":"Xinglong Zhang, Jiali Li, Zihan Zhang, Huiwen Zheng, Heng Li, Yifan Zhang, Xin Zhao, Yingyan Li, Jingjing Wang, Yun Liao, Li Yu, Heng Zhao, Dandan Li, Haijing Shi, Longding Liu","doi":"10.1016/j.antiviral.2026.106557","DOIUrl":"10.1016/j.antiviral.2026.106557","url":null,"abstract":"<div><div>Coxsackievirus Group B (CVB) remains an important cause of severe disease in infants and young children, including viral myocarditis and meningitis, yet no licensed vaccine or virus-specific antiviral therapy is currently available. Here, we engineered soluble Coxsackievirus and adenovirus receptor (CAR) ectodomains and displayed the optimized receptor decoy on ferritin nanoparticles to generate a potent anti-CVB3 entry inhibitor. Wild-type soluble CAR ectodomains neutralized CVB3 but were limited by homodimerization and by residual binding to endogenous CAR/JAML, which was associated with dose-dependent mitogenic activity. Guided by structural information, we introduced mutations that abolished dimerization and CAR/JAML binding while preserving, and further improving, viral neutralization. Ferritin display of the optimized sCAR1 mutant enhanced multivalent presentation, systemic persistence, and tissue delivery. The resulting sCAR1 Mu + Ferritin nanoparticle achieved IC<sub>50</sub> values of 413 ng/mL in Vero cells and 140 ng/mL in SH-SY5Y cells. In neonatal BALB/c mice, prophylactic administration of sCAR1 Mu + Ferritin (200 μg, 6 h before challenge) conferred 68.75% protection against lethal CVB3 infection (10<sup>3.5</sup> CCID<sub>50</sub>), reduced viral burden in the liver, spleen, brain, and heart, and alleviated myocarditis and neuroinflammation without sustained cytokine activation. Cross-neutralizing activity against CVB1 further supports the breadth of this receptor-based platform. These findings identify ferritin-displayed engineered CAR nanoparticles as a safety-optimized and mutation-resilient antiviral strategy for CVB infections.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"255 ","pages":"Article 106557"},"PeriodicalIF":4.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antiviral researchPub Date : 2026-11-01Epub Date: 2026-10-26DOI: 10.1016/j.antiviral.2026.106556
Federica Giammarino, Maarten AA. van de Klundert, Francesco Saladini, Maurizio Zazzi, Anders Sönnerborg, Rafael Ceña-Diez
{"title":"WG-am combinations restore antiviral potency against fostemsavir and lenacapavir-resistant HIV-1","authors":"Federica Giammarino, Maarten AA. van de Klundert, Francesco Saladini, Maurizio Zazzi, Anders Sönnerborg, Rafael Ceña-Diez","doi":"10.1016/j.antiviral.2026.106556","DOIUrl":"10.1016/j.antiviral.2026.106556","url":null,"abstract":"<div><h3>Background</h3><div>Resistance to fostemsavir (FTR) and lenacapavir (LEN) poses critical challenges for heavily treatment-experienced (HTE) people with HIV-1 who have exhausted conventional therapeutic options. We evaluated the antiviral synergy of tryptophylglycine-amide (WG-am), a naturally occurring dipeptide from HIV-1 elite controllers that inhibits viral entry and reverse transcription, in combination with seven antiretrovirals against FTR- and LEN-resistant HIV-1 viruses.</div></div><div><h3>Methods</h3><div>Combination assays were performed in TZM-bl cells using a 7×7 dose-matrix format against nine HIV-1 viruses with defined FTR- or LEN-resistance mutations. Synergy was quantified using the zero-interaction potency (ZIP) model in SynergyFinder across all concentrations and at the ≥90% viral inhibition threshold. Three priority combinations — with ibalizumab (IBA), darunavir (DRV), and FTR — were validated in activated PBMCs from three independent donors.</div></div><div><h3>Results</h3><div>WG-am demonstrated synergistic or additive interactions with all seven antiretrovirals; no antagonism was detected. IBA and DRV showed the highest and most consistent synergy across both resistance backgrounds. FTR showed paradoxical synergy against FTR-resistant virus (peak ZIP 15.58 against S375T). At the ≥90% inhibition threshold, 87.3% (55/63) of combination pairs were synergistic. PBMC validation confirmed synergy for all six priority combinations (ZIP 11.01–17.19), with WG-am + FTR scores exceeding TZM-bl values in primary cells.</div></div><div><h3>Conclusions</h3><div>WG-am-based combinations demonstrate synergistic antiviral activity against FTR- and LEN-resistant HIV-1 in reporter cells and primary immune cells. IBA, DRV, and FTR are identified as priority combination partners for WG-am as a component of resistance-informed salvage regimens for HTE patients with limited treatment options.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"255 ","pages":"Article 106556"},"PeriodicalIF":4.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149261326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Corrigendum to “Construction of a suckling mouse model based on an EV-C96 clinical isolate and its application in drug screening and vaccine development” [Antivir. Res. 254 (2026) 106511]","authors":"Jing Wang, Ying Qu, Yunyi He, Qiu Yang, Hanyu Zhu, Yongbei Chen, Xianlong Duan, Huanying Zheng, Shengjun Xiao, Qiliang Liu, Hongbo Liu","doi":"10.1016/j.antiviral.2026.106543","DOIUrl":"10.1016/j.antiviral.2026.106543","url":null,"abstract":"","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"255 ","pages":"Article 106543"},"PeriodicalIF":4.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149103408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antiviral researchPub Date : 2026-03-01Epub Date: 2026-01-20DOI: 10.1016/j.antiviral.2026.106355
Zak T. Janetzki , Laura C. McCoullough , Peter A. Revill , Margaret Littlejohn
{"title":"Overview of gene editing strategies against HBV","authors":"Zak T. Janetzki , Laura C. McCoullough , Peter A. Revill , Margaret Littlejohn","doi":"10.1016/j.antiviral.2026.106355","DOIUrl":"10.1016/j.antiviral.2026.106355","url":null,"abstract":"<div><div>254 million people currently live with chronic hepatitis B virus (HBV) infection, with over 1 million deaths annually due to complications such as cirrhosis and hepatocellular carcinoma. Although current direct-acting antivirals suppress HBV replication, they do not eliminate the virus and rarely lead to HBV functional cure, defined as the loss of serum hepatitis B surface antigen (HBsAg) and DNA. A major barrier to achieving HBV functional cure is the HBV covalently closed circular DNA minichromosome (cccDNA), which hides from the immune system in the nucleus of an infected cell, and is very stable. Another barrier is integration of incomplete HBV genomes into the host genome, which is the main source of HBsAg in later disease stages, and is difficult to target without impacting the human genome. New direct-acting antivirals are required that target different stages of the HBV replication cycle, including the HBV cccDNA and integrated DNA to improve rates of functional cure. The development of gene editing tools provides an opportunity to develop novel therapies that target the HBV cccDNA, integrated DNA and HBV RNA. This review explores the different gene editing tools that have been used to target the HBV cccDNA, integrated DNA and RNA.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"247 ","pages":"Article 106355"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antiviral researchPub Date : 2026-03-01Epub Date: 2026-01-14DOI: 10.1016/j.antiviral.2026.106344
Yunzhe Kang , Rui Wang , Lulu Yao , Xiuwen Yang , Wenhui Zhu , Lele Wang , Gaiping Zhang , Guoqing Zhuang , Aijun Sun
{"title":"The UL23 thymidine kinase of Marek's disease virus is a target for anti-HSV drug development","authors":"Yunzhe Kang , Rui Wang , Lulu Yao , Xiuwen Yang , Wenhui Zhu , Lele Wang , Gaiping Zhang , Guoqing Zhuang , Aijun Sun","doi":"10.1016/j.antiviral.2026.106344","DOIUrl":"10.1016/j.antiviral.2026.106344","url":null,"abstract":"<div><div>Marek's disease virus (MDV) is an oncogenic alphaherpesvirus causing rapid onset of malignant T-cell lymphomas in chickens. <em>UL23</em>-encoded thymidine kinase (TK) has highly conserved sequences in distinctive alphaherpesviruses. However, its enzymatic activity in viral replication and pathogenesis is poorly understood. Here, we found that the nucleotide-binding sites and the functional domains related to activity of TK from different alphaherpesviruses are strongly conserved. We show that an MDV-1 <em>UL23</em>-null mutation (Md5BACΔ<em>UL23</em>) significantly reduces MDV replication <em>in vitro</em> and <em>in vivo</em>. Interestingly, chimeric viruses with replacement of MDV-1 <em>UL23</em> with MDV-2, HVT, PRV, or HSV-1 <em>UL23</em> showed partial recovery of MDV replication and pathogenicity. In addition, Md5BACΔ<em>UL23</em> infection resulted in higher survival rate and lower MDV-specific tumor incidence, which could be partially compensated by chimeric viruses. The replication properties of <em>UL23</em> chimeric alphaherpesviruses are susceptible to acyclovir inhibition, whereas Md5BACΔ<em>UL23</em> exhibits complete resistance. Overall, our establishment of the MDV-TK chimeric model provides a robust basis for evaluating TK-targeted therapeutics, accelerating clinical translation of novel anti-herpesvirus strategies.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"247 ","pages":"Article 106344"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145987929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antiviral researchPub Date : 2026-03-01Epub Date: 2026-01-30DOI: 10.1016/j.antiviral.2026.106358
Halef Okan Doğan , Seyit Ali Büyüktuna , Gözde Ertürk Zararsız , Serra İlayda Yerlitaş , Ahu Cephe , Ahmet Turan Koç , Rıdvan Karaarslan , Zülal Peri Yoldaş Aslanoğlu , Merve Gülşah Lafçı , Meltem Kurt Yenihan , Alperen Aydemir , Ebrar Büşra Yıldırım , Gökmen Zararsız
{"title":"Targeted organic acid profiling in Crimean-Congo hemorrhagic fever: A metabolomics-based approach to biomarker discovery","authors":"Halef Okan Doğan , Seyit Ali Büyüktuna , Gözde Ertürk Zararsız , Serra İlayda Yerlitaş , Ahu Cephe , Ahmet Turan Koç , Rıdvan Karaarslan , Zülal Peri Yoldaş Aslanoğlu , Merve Gülşah Lafçı , Meltem Kurt Yenihan , Alperen Aydemir , Ebrar Büşra Yıldırım , Gökmen Zararsız","doi":"10.1016/j.antiviral.2026.106358","DOIUrl":"10.1016/j.antiviral.2026.106358","url":null,"abstract":"<div><div>Crimean-Congo Hemorrhagic Fever (CCHF) is a severe tick-borne viral infection associated with high morbidity and mortality. Understanding the metabolic alterations associated with the disease may uncover novel biomarkers for diagnosis and disease severity assessment. In this study, we conducted a targeted metabolomic analysis using LC-MS/MS to quantify serum organic acid levels in 115 CCHF-positive patients, 30 CCHF-negative patients, and 45 healthy controls. This is the first study to comprehensively profile organic acid alterations in CCHFV using targeted metabolomics. Our findings revealed that several organic acids, notably alpha-ketoglutaric acid, malic acid, p-hydroxyphenyllactic acid, and 3-hydroxyisobutyric acid, were significantly elevated in CCHFV patients and positively correlated with markers of inflammation and coagulation. These metabolites demonstrated strong prognostic performance for intensive care unit (ICU) admission. Additionally, survival analysis indicated that elevated levels of specific organic acids were associated with increased mortality risk. Pathway enrichment analysis identified dysregulation of the TCA cycle, pyruvate metabolism, and amino acid pathways in CCHF patients. Our results suggest that specific organic acids may serve as novel biomarkers for disease severity and prognosis, offering potential tools for early risk stratification and improved clinical management of CCHF.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"247 ","pages":"Article 106358"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146099605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Therapeutic intranasal delivery of NanoSTING provides broad protection against seasonal and highly pathogenic influenza strains","authors":"Ankita Leekha , Kate Reichel , Brett Hurst , Navin Varadarajan","doi":"10.1016/j.antiviral.2026.106342","DOIUrl":"10.1016/j.antiviral.2026.106342","url":null,"abstract":"<div><div>Influenza is a major global threat due to several factors, including great zoonotic potential, ongoing antigenic drift, limited effectiveness of current vaccines, and the emergence of drug-resistant viral strains. Broad-spectrum therapeutic regimens that can treat vulnerable populations, enable faster resolution of symptoms, and decrease fatality rates are a long-sought objective for influenza. Here, we report the development of NanoSTING, a liposomally encapsulated STING agonist (cGAMP), as a single-dose intranasal treatment of influenza. We demonstrate that NanoSTING is stable under simple refrigeration conditions, with no loss of encapsulated cGAMP, for up to a year. A single dose of NanoSTING administered intranasally induced robust type I interferon responses in the nasal and lung tissue of mice without observable toxicity. In mouse challenge models of influenza A (H1N1 or highly pathogenic H5N1) and influenza B, NanoSTING provided therapeutic protection at least as effective as ten doses of oseltamivir. NanoSTING demonstrated therapeutic efficacy even when administered 48–72 h post-infection. Furthermore, NanoSTING maintained its activity in aged and immunocompromised mice, as evidenced by the robust induction of interferon responses in nasal tissues, highlighting its potential for use in vulnerable individuals. These attributes of NanoSTING support its potential use as a promising host-directed anti-viral with a large therapeutic window and broad-spectrum efficacy.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"247 ","pages":"Article 106342"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145987548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antiviral researchPub Date : 2026-03-01Epub Date: 2026-01-21DOI: 10.1016/j.antiviral.2026.106354
Zexin Liu , Guohong Wu , Jianwei Mao , Yutong Zheng , Qizhen Fu , Sifan Lin , Yizhou Chen , Weisan Chen , Pei Zhou , Jianxin Chen
{"title":"Lapachol, a dihydroorotate dehydrogenase inhibitor, demonstrates antiviral activity against feline calicivirus in vitro and in vivo","authors":"Zexin Liu , Guohong Wu , Jianwei Mao , Yutong Zheng , Qizhen Fu , Sifan Lin , Yizhou Chen , Weisan Chen , Pei Zhou , Jianxin Chen","doi":"10.1016/j.antiviral.2026.106354","DOIUrl":"10.1016/j.antiviral.2026.106354","url":null,"abstract":"<div><div>Feline calicivirus (FCV) infection poses a significant threat to domestic cats, causing a spectrum of clinical symptoms ranging from mild respiratory issues to severe systemic diseases. Although FCV vaccines are available, their protective efficacy is limited by the extensive genetic diversity and antigenic variability of FCV. To date, no approved antiviral drug is available, highlighting the urgent need for effective therapeutics. Here, we screened a library of 431 small-molecule compounds to identify novel antiviral agents against FCV, leading to the discovery of ten new inhibitors, including five naphthoquinones. Among these, lapachol demonstrated the most potent anti-FCV activity, with a half-maximal effective concentration (EC<sub>50</sub>) of 1.87 μM and a selectivity index (SI) of 677. Mechanistic studies revealed that lapachol exerts its antiviral effects by inhibiting feline dihydroorotate dehydrogenase (DHODH), thereby disrupting the synthesis of pyrimidine nucleotides, which are essential for viral replication. Further investigations showed that silencing DHODH enhanced lapachol's antiviral activity, while supplementation with pyrimidine nucleotides or DHODH overexpression reversed its effects. Importantly, oral administration of lapachol at 5 mg/kg significantly reduced virus shedding from the oral and nasal cavities in FCV-infected cats, promoted recovery from weight loss, and alleviated oral ulceration and pulmonary lesions, without inducing observable hepatic or renal toxicity. These findings demonstrate that lapachol is a promising candidate for the treatment of FCV infections, and underscore the potential of DHODH as a viable therapeutic target for antiviral drug development.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"247 ","pages":"Article 106354"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antiviral researchPub Date : 2026-03-01Epub Date: 2026-01-24DOI: 10.1016/j.antiviral.2026.106357
Yuanmei Zhu , Huihui Chong , Nian Liu, Yuxian He
{"title":"Pharmacokinetics and safety of HIV fusion inhibitor Lipovirtide in non-human primates","authors":"Yuanmei Zhu , Huihui Chong , Nian Liu, Yuxian He","doi":"10.1016/j.antiviral.2026.106357","DOIUrl":"10.1016/j.antiviral.2026.106357","url":null,"abstract":"<div><div>Lipovirtide, also known as LP-80, is a lipopeptide-based HIV fusion inhibitor with potent broad-spectrum and long-lasting antiviral activity. We recently reported the pharmacokinetics and safety of Lipovirtide in rats (Zhu et al. 2025); herein, its pharmacokinetics and safety profiles in cynomolgus macaques were systematically evaluated. Lipovirtide was rapidly absorbed after subcutaneous administration, with absolute bioavailability (F) of 110.11 % in male and 92.33 % in female. The time to reach maximum plasma concentration (T<sub>max</sub>) ranged from 4 to 8 h, and the terminal half-life (T<sub>1/2</sub>) was between 10.18 and 13.51 h. Comprehensive safety assessments revealed no significant effects on cardiovascular or respiratory functions in conscious macaques after a single subcutaneous administration. General toxicity studies demonstrated its excellent tolerability, with a maximum tolerated dose above 150 mg/kg for single dosing; the 4-week and 39-week repeated dosing determined the no-observed-adverse-effect level (NOAEL) to be 15 mg/kg. Toxicokinetic analyses confirmed that long-term administration did not lead to drug accumulation in both male and female animals. No anti-drug antibody (ADA) formation was observed throughout the study schedule. Collectively, our preclinical characterizations provide compelling data to support the clinical development of Lipovirtide, which has already progressed to a phase III clinical trial.</div></div>","PeriodicalId":8259,"journal":{"name":"Antiviral research","volume":"247 ","pages":"Article 106357"},"PeriodicalIF":4.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}